ArticleJournal of food science2026
Avenanthramide C From Oats Possibly Exerts Anti-Inflammatory Effects in Human Umbilical Vein Endothelial Cells.
Article in Journal of food science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Avenanthramide C From Oats Possibly Exerts Anti-Inflammatory Effects in Human Umbilical Vein Endothelial Cells.Journal of food science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic kidney disease (CKD) is associated with inflammation and cardiovascular complications and is partly exacerbated by the uremic toxin indoxyl sulfate (IS). IS is known to activate the aryl hydrocarbon receptor (AhR) to promote vascular inflammation. On the other hand, avenanthramide C (Ave), an oat-derived polyphenol, has antioxidative and anti-inflammatory properties. Therefore, we investigated whether Ave can suppress IS-induced inflammatory responses. Analysis of serum from hemodialysis patients revealed a significant correlation between IS and interleukin-6 (IL-6) levels. In human umbilical vein endothelial cells (HUVECs), IS (≥50 µg/mL) increased IL-6 secretion, while Ave (≥10 µM) suppressed this effect. Docking simulations and in vitro experiments suggested that Ave may interact with AhR and suppress IS-induced expression of AhR target genes, including that of cytochrome P450 family 1 subfamily A member 1. High-performance liquid chromatography verified the uptake of Ave by human umbilical vein endothelial cells. Additionally, the anti-inflammatory effects of Ave were independent of the adrenergic α1 receptor, adenosine monophosphate-activated protein kinase pathways, and protein kinase B pathways. Ave suppresses IS-induced inflammation, thereby reducing IL-6 secretion in HUVECs. These findings suggest the potential of Ave as a dietary intervention for mitigating vascular inflammation in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.